Want to see WOK full AI Analyst Report?
WORK Medical Technology Group LTD (WOK) AI Stock Analysis
WORK Medical Technology Group LTD
(NASDAQ:WOK)
The score is held back primarily by deteriorated profitability and contracting revenue, alongside bearish technical momentum. Offsetting this, leverage improved and cash flow rebounded in the latest year, but the lack of meaningful valuation support (negative earnings and no dividend data) keeps the overall profile below average.
WORK Medical Technology Group LTD (WOK) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.29M
- Dividend Yield
- ―
- Average Volume (3M)
- 193.32K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 0.98
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 238
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
WORK Medical Technology Group LTD Business Overview & Revenue Model
Company Description
WORK Medical Technology Group LTD, through with its subsidiaries, manufactures and sells medical consumables and devices in the People's Republic of China and internationally. The company offers medical face masks, artery compression tourniquets, end...
How the Company Makes Money
null
WORK Medical Technology Group LTD Financial Statement Overview
Summary
Fundamentals are mixed: revenue has been shrinking and profitability remains negative, but the balance sheet leverage improved materially and operating/free cash flow rebounded strongly in the latest year. The key risk is still weak earnings power and an unfavorable top-line trend.
Income Statement
28NegativeBalance Sheet
62PositiveCash Flow
55Neutral| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.72M | 9.85M | 11.51M | 13.57M | 19.71M | 45.86M |
| Gross Profit | 1.31M | 2.34M | 2.87M | 4.14M | 4.42M | 8.64M |
| EBITDA | -3.19M | 339.37K | -1.71M | 2.08M | 4.72M | 11.87M |
| Net Income | -4.50M | -1.07M | -3.49M | 112.03K | 865.21K | 5.96M |
Balance Sheet | ||||||
| Total Assets | 48.32M | 33.16M | 36.25M | 29.96M | 25.54M | 30.66M |
| Cash, Cash Equivalents and Short-Term Investments | 3.25M | 4.09M | 6.56M | 1.60M | 731.18K | 508.71K |
| Total Debt | 6.62M | 6.45M | 13.47M | 9.10M | 6.30M | 6.60M |
| Total Liabilities | 15.83M | 11.99M | 20.18M | 18.97M | 14.35M | 19.26M |
| Stockholders Equity | 30.13M | 18.35M | 13.19M | 9.88M | 10.00M | 10.04M |
Cash Flow | ||||||
| Free Cash Flow | -5.62M | 4.91M | -11.49M | 1.63M | -4.27M | -7.24M |
| Operating Cash Flow | -865.76K | 6.24M | -2.23M | 2.21M | -2.26M | -7.18M |
| Investing Cash Flow | -13.89M | -7.61M | -9.06M | -583.30K | -1.35M | -60.00K |
| Financing Cash Flow | 16.41M | -898.21K | 15.66M | -728.72K | 3.57M | 7.99M |
WORK Medical Technology Group LTD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WOK, the sentiment is Negative. The current price of 0.94 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.58, and below the 200-day MA of 57.87, indicating a bearish trend. The MACD of -0.20 indicates Negative momentum. The RSI at 29.45 is Positive, neither overbought nor oversold. The STOCH value of 9.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WOK.
WORK Medical Technology Group LTD Risk Analysis
WORK Medical Technology Group LTD disclosed 83 risk factors in its most recent earnings report. WORK Medical Technology Group LTD reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksWORK Medical Technology Group LTD Peers Comparison
Overall Rating
- WOK47Neutral
GCTK38Underperform
LUCY38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| WOK | 47Neutral | $4.11M | -0.00 | -18.55% | ― | ― | ― |
| GCTK | 38Underperform | $449.96K | -0.00 | -2135.52% | ― | ― | 99.51% |
| LUCY | 38Underperform | $7.15M | -0.61 | -88.90% | ― | 72.50% | 58.34% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| WOK | WORK Medical Technology Group LTD | 0.94 | -38599.06 | -100.00% | |
| GCTK | Glucotrack, Inc. | 0.30 | -166.50 | -99.82% | |
| LUCY | Innovative Eyewear, Inc. | 0.82 | -0.72 | -46.43% |
WORK Medical Technology Group LTD Corporate Events
WORK Medical Technology Group Sets Up U.S. Subsidiary and Steps Up Global Outreach
WORK Medical Technology Group LTD, a Chinese medical device supplier with FDA-registered products and international sales, is deepening its overseas footprint through a new U.S. structure. The company, listed on Nasdaq under the ticker WOK, already d...
WORK Medical Technology Group Shifts Headquarters to New Zealand with New Subsidiary
WORK Medical Technology Group LTD, a Cayman Islands–incorporated medical technology company, has shifted its operational hub to New Zealand as it targets growth in the Australasian market. The company’s structure includes a wholly owned B...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Feb 07, 2026